Year-end Report 1 October – 31 December 2021

Report this content
  • Despite pandemic related challenges: 30% sales growth and surgeries in 15 countries during 2021
  • Episurf Medical’s first 510(k) submission completed in line with timetable. FDA review ongoing
  • Commercial organisation expanded with Head of Sales OUS, re-start of commercial activities following the end of the pandemic

”Approaching the end of the pandemic is a relief on a human level, far beyond business life. However, it is fair to say that wearing the Episurf jersey during the pandemic has been extremely tough. Elective surgery has been severely hit, with experimental elective surgery even more so. Hence, that we have been able to deliver growth throughout the pandemic, and that we now, finally, are expecting a return to normalcy, is just highly encouraging. We are in a better position than ever, with a strengthened organisation, several products in the pipeline, a strong scientific foundation to operate from, regulatory access to several markets globally, and a strong financial position. We are very optimistic about the future, and although Q1 2022 still offers some COVID-related challenges, we expect to take significant steps during 2022”, says Pål Ryfors, CEO Episurf Medical.

Fourth quarter 2021 compared to 2020, Group

  • Gross order intake amounted to SEK 1.6m (1.3), an increase of 23%
  • Order book amounted to SEK 1.3m (1.3)
  • Group net sales amounted to SEK 1.5m (1.5)
  • Loss for the period amounted to SEK -18.9m (-16.2)
  • Earnings per share amounted to SEK -0.08 (-0.08)

Twelve months 2021 compared to 2020, Group

  • Gross order intake amounted to SEK 6.6m (5.6), an increase of 18%
  • Group net sales increased by 30% to SEK 6.5m (5.0)
  • Loss for the period amounted to SEK -69.3m (-63.9)
  • Earnings per share amounted to SEK -0.31 (-0.39)

Significant events during the fourth quarter

  • Episurf Medical carried out a directed share issue of SEK 159m. Ilija Batljan entered as the largest shareholder
  • Episurf Medical submitted 510(k) application for Episealer® Patellofemoral System
  • Episurf Medical’s implants approved for sale in Saudi Arabia
  • Episurf Medical hired Stephen Caswell to head Global Sales OUS

Significant events after the fourth quarter

  • Episurf Medical’s implants approved for sale in Malaysia

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website:

This information is information that Episurf Medical AB is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 11 February 2022.



Documents & Links